Here's a great opportunity to participate in an advanced prostate cancer marketing survey, earn $40 dollars for yourself and help move our understanding of our disease just a little bit further forward. *What is the purpose?* Understanding patients' knowledge and perceptions of treatments for prostate cancer, so researchers can understand how prostate cancer affects patients [...]
Many of us in the United States with advanced prostate cancer who have failed Zytiga are looking to enter the Early Access MDV-3100 Clinical Trial. However, you need to be aware that there are some requirements you will need to meet prior to starting MDV-3100. You will need to wait 30 days after stopping Zytiga [...]
Recently, it was announced that there was a submission by Astellas and Medivation to the European Regulatory Agency for Enzalutamide (MDV-3100) for the treatment of men with advanced prostate cancer post-chemotherapy The basis of the submission was the pivotal phase 3 AFFIRM study. The Marketing Authorization Application (MAA) that was made to the European Medicines [...]
Not in the normal realm of advanced prostate cancer, but important for the prostate cancer world is the news that the FDA has approved a new screening test for prostate cancer. The currently used screening tool, the PSA has only a 55% accuracy rate and as recently run into serious trouble with The U.S. Preventive [...]
There has been an on-going debate on the advanced prostate cancer on-line support group about the issue of the efficacy of Provenge in light of the expectation of a person's increasing PSA number while getting the treatment. For many men with advanced prostate cancer this is a reason they elect to pass on this treatment [...]